Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietar ...
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA ® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results